DAUNORUBICINIt is a cell cycle nonspecific agent, but its cytotoxic effects are most marked on cells in the S-phase.
Acute non-lymphocytic leukemia, acute lymphocytic leukemia, HIV related Kaposi's sarcoma.
Non lymphocytic leukemia: 30-40 mg/sq-m/day on days 1,2 & 3 of first course and on days 1,2 of subsequent courses. Acute lymphocytic leukemia: Adult: 45 mg/sq-m/day IV on days 1,2 & 3. Children: 25 mg/sq-m/day on day 1 every week IV. HIV related Kaposi's sarcoma: 40 mg/sq-m every two weeks.
Pregnancy, lactation, elderly, liver dysfunction.
Bone marrow suppression, cardiac toxicity, cardiomyopathy and CCF.
Immunization with live vaccines not recommended as daunorubicin is immunosuppressant. Concurrent radiation leads to enhanced radiation reaction.
|Brand Name||Manufactured by|
|DAUNOCIN||MIRACALUS PHARMA PVT. LTD.|